Home > Insider Trading > Filing (0001213900-14-008002)

Filing Details

Accession Number:: 0001213900-14-008002
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-11-12 20:10:55
Reporting Period:: 2014-11-10

Filing Date:: 2014-11-12
Accepted Time:: 2014-11-12 20:10:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1503802	Karyopharm Therapeutics Inc.	KPTI	Pharmaceutical Preparations (2834)	263931704

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1590232	Ltd Chione	Simou Menardou 8 Ria Court 8, Office 101 6015 Larnaca G4	No	No	Yes	No
1591256	Andreas Hadjimichael	Simou Menardou 8, Ria Court 8, Office 101 6015 Larnaca G4	No	No	Yes	No
1591257	Amalia Hadjimichael	Simou Menardou 8, Ria Court 8, Office 101 6015 Larnaca G4	No	No	Yes	No
1591274	Wiaczeslaw Smolokowski	Chalet Lenotchka Ch.de Barnoud 1885 Chesieres Switzerland G4 00000	No	No	Yes	No
1591275	Marcin Czernik	Simou Menardou 8, Ria Court 8, Office 101 6015 Larnaca G4	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2014-11-10	31,400	$42.65	9,719,583	No	4	S	Direct
Common Stock	Disposition	2014-11-10	23,100	$43.80	9,696,483	No	4	S	Direct
Common Stock	Disposition	2014-11-10	10,300	$44.73	9,686,183	No	4	S	Direct
Common Stock	Disposition	2014-11-10	200	$45.49	9,685,983	No	4	S	Direct
Common Stock	Disposition	2014-11-11	54,100	$42.51	9,631,883	No	4	S	Direct
Common Stock	Disposition	2014-11-12	38,800	$42.26	9,593,083	No	4	S	Direct
Common Stock	Disposition	2014-11-12	6,200	$43.19	9,586,883	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Except as otherwise noted, the prices reported in Column 4 are weighted average prices. The 31,400 shares referred to in the first row of Column 4 were sold at prices ranging from $42.25 to $43.24, inclusive. The 23,100 shares referred to in the second row of Column 4 were sold at prices ranging from $43.255 to $44.245, inclusive. The 10,300 shares referred to in the third row of Column 4 were sold at prices ranging from $44.275 to $45.14, inclusive. The 200 shares referred to in the fourth row of Column 4 were sold at the $45.49 price indicated. The 54,100 shares referred to in the fifth row of Column 4 were sold at prices ranging from $42.50 to $42.77, inclusive. The 38,800 shares referred to in the sixth row of Column 4 were sold at prices ranging from $42.00 to $42.745, inclusive. The 6,200 shares referred to in the seventh row of Column 4 were sold at prices ranging from $43.00 to $43.71, inclusive.
The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth in this footnote.
Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and Amalia Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione.
Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed, except, with respect to any person, to the extent of the pecuniary interest of such person in such securities.
Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.